Sutter Health | MedPath

CAR T-cell Therapies Show Promise in Relapsed Multiple Myeloma

4 months ago

• Allogeneic BCMA CAR T-cell therapy demonstrates promising efficacy and reasonable safety in relapsed multiple myeloma, utilizing CRISPR technology to mitigate graft-versus-host disease. • A clinical trial targeting GPRC5D shows high efficacy in patients who have relapsed after BCMA-targeted therapy, potentially offering a more favorable treatment option. • The allogeneic approach allows for faster treatment delivery using "off-the-shelf" cells, addressing a key limitation of autologous CAR T-cell therapies. • Early results indicate high efficacy in minority patients, who are often underrepresented in clinical trials, highlighting the therapy's potential for broader impact.

Oncology Pharmacists Expand Clinical Roles, Push for Provider Status Recognition

5 months ago

• Leading cancer centers demonstrate pharmacists' expanding roles in direct patient care, including running therapeutic clinics, managing treatment protocols, and interpreting pharmacogenomic test results. • Pharmacists are increasingly involved in clinical trials management, improving patient enrollment through medication reconciliation and coordination with other healthcare providers. • Despite proven value in oncology care delivery, pharmacists face ongoing challenges in achieving federal recognition as providers, limiting reimbursement opportunities and resource allocation.

Real-World Leqembi Use Shows Comparable Safety to Clinical Trials

6 months ago

• Real-world data from the U.S. shows lecanemab's ARIA rates are consistent with clinical trials, despite a broader patient population with more comorbidities. • In Japan, lecanemab use is growing rapidly, with ARIA rates half those observed in the U.S., mirroring findings from the Phase 3 Clarity trial. • Excluding APOE4 homozygotes from lecanemab treatment may improve cognitive outcomes and reduce ARIA risk, influencing EMA's recommendation for approval. • Monitoring protocols and multidisciplinary care are crucial for managing lecanemab treatment, ensuring appropriate MRI monitoring and patient safety.

Immix Biopharma Expands NXC-201 Clinical Trial Sites for AL Amyloidosis

9 months ago

• Immix Biopharma broadens its NEXICART-2 trial for relapsed/refractory AL Amyloidosis by incorporating new clinical sites, enhancing patient accessibility. • The expansion includes leading AL Amyloidosis programs at Cleveland Clinic, UC Davis, and Sutter Health, with Memorial Sloan Kettering Cancer Center as the lead site. • NXC-201, a BCMA-targeted CAR-T cell therapy, demonstrated a 92% overall response rate in an ex-U.S. trial, showing promise for this challenging disease. • The NEXICART-2 trial aims to evaluate the safety and efficacy of NXC-201 in patients who have not previously received BCMA-targeted therapy.